Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01586403 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Primary completion date: Sep 2013 to Sep 2028v3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 15 to confirmed 14
    • Study sites: 2 to 1
    • Study description expanded, about 90 words
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 2012 to Jul 2012
    • Study sites: 1 to 2
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Loyola University
22 trials monitored
See 1 trial at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
Trial Details
NCT Number NCT01586403
Lead Sponsor Loyola University
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Melanoma
Related terms Melanoma
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov